Cargando…

Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer

BACKGROUND: Nomograms are rarely employed to estimate the survival of patients with advanced and metastatic pancreatic cancer (PC). Herein, we developed a comprehensive approach to using a nomogram to predict survival probability in patients with advanced and metastatic PC. Methods: A total of 323 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, G. C., Lv, Y., Yan, H., Sun, D. C., Qu, T. T., Pan, Y. T., Han, Q. L., Dai, G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594118/
https://www.ncbi.nlm.nih.gov/pubmed/34781928
http://dx.doi.org/10.1186/s12885-021-08943-w
_version_ 1784599901823303680
author Deng, G. C.
Lv, Y.
Yan, H.
Sun, D. C.
Qu, T. T.
Pan, Y. T.
Han, Q. L.
Dai, G. H.
author_facet Deng, G. C.
Lv, Y.
Yan, H.
Sun, D. C.
Qu, T. T.
Pan, Y. T.
Han, Q. L.
Dai, G. H.
author_sort Deng, G. C.
collection PubMed
description BACKGROUND: Nomograms are rarely employed to estimate the survival of patients with advanced and metastatic pancreatic cancer (PC). Herein, we developed a comprehensive approach to using a nomogram to predict survival probability in patients with advanced and metastatic PC. Methods: A total of 323 patients with advanced and metastatic PC were identified from the Chinese People’s Liberation Army (PLA) General Hospital. A baseline nomogram was constructed using baseline variables of 323 patients. Additionally, 233 patients, whose tumors showed initial responses to first-line chemotherapy, were enrolled in the chemotherapy response-based model. 128 patients and 108 patients with advanced and metastatic PC from January 2019 to April 2021 were selected for external validating baseline model and chemotherapy response-based model. The 1-year and 2-year survival probability was evaluated using multivariate COX regression models. The discrimination and calibration capacity of the nomograms were assessed using C-statistic and calibration plots. The predictive accuracy and net benefit of the nomograms were evaluated using ROC curve and DCA, respectively. RESULTS: In the baseline model, six variables (gender, KPS, baseline TB, baseline N, baseline WBC and baseline CA19–9) were used in the final model. In the chemotherapy response-based model, nine variables (KPS, gender, ascites, baseline N, baseline CA 19–9, baseline CEA, change in CA 19–9 level at week, change in CEA level at week and initial response to chemotherapy) were included in the final model. The C-statistics of the baseline nomogram and the chemotherapy response-based nomogram were 0.67 (95% CI, 0.62–0.71) and 0.74 (95% CI, 0.69–0.77), respectively. CONCLUSION: These nomograms were constructed to predict the survival probability of patients of advanced and metastatic PC. The baseline model and chemotherapy response-based model performed well in survival prediction. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08943-w.
format Online
Article
Text
id pubmed-8594118
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85941182021-11-16 Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer Deng, G. C. Lv, Y. Yan, H. Sun, D. C. Qu, T. T. Pan, Y. T. Han, Q. L. Dai, G. H. BMC Cancer Research BACKGROUND: Nomograms are rarely employed to estimate the survival of patients with advanced and metastatic pancreatic cancer (PC). Herein, we developed a comprehensive approach to using a nomogram to predict survival probability in patients with advanced and metastatic PC. Methods: A total of 323 patients with advanced and metastatic PC were identified from the Chinese People’s Liberation Army (PLA) General Hospital. A baseline nomogram was constructed using baseline variables of 323 patients. Additionally, 233 patients, whose tumors showed initial responses to first-line chemotherapy, were enrolled in the chemotherapy response-based model. 128 patients and 108 patients with advanced and metastatic PC from January 2019 to April 2021 were selected for external validating baseline model and chemotherapy response-based model. The 1-year and 2-year survival probability was evaluated using multivariate COX regression models. The discrimination and calibration capacity of the nomograms were assessed using C-statistic and calibration plots. The predictive accuracy and net benefit of the nomograms were evaluated using ROC curve and DCA, respectively. RESULTS: In the baseline model, six variables (gender, KPS, baseline TB, baseline N, baseline WBC and baseline CA19–9) were used in the final model. In the chemotherapy response-based model, nine variables (KPS, gender, ascites, baseline N, baseline CA 19–9, baseline CEA, change in CA 19–9 level at week, change in CEA level at week and initial response to chemotherapy) were included in the final model. The C-statistics of the baseline nomogram and the chemotherapy response-based nomogram were 0.67 (95% CI, 0.62–0.71) and 0.74 (95% CI, 0.69–0.77), respectively. CONCLUSION: These nomograms were constructed to predict the survival probability of patients of advanced and metastatic PC. The baseline model and chemotherapy response-based model performed well in survival prediction. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08943-w. BioMed Central 2021-11-15 /pmc/articles/PMC8594118/ /pubmed/34781928 http://dx.doi.org/10.1186/s12885-021-08943-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Deng, G. C.
Lv, Y.
Yan, H.
Sun, D. C.
Qu, T. T.
Pan, Y. T.
Han, Q. L.
Dai, G. H.
Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
title Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
title_full Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
title_fullStr Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
title_full_unstemmed Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
title_short Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
title_sort nomogram to predict survival of patients with advanced and metastatic pancreatic cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594118/
https://www.ncbi.nlm.nih.gov/pubmed/34781928
http://dx.doi.org/10.1186/s12885-021-08943-w
work_keys_str_mv AT denggc nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer
AT lvy nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer
AT yanh nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer
AT sundc nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer
AT qutt nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer
AT panyt nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer
AT hanql nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer
AT daigh nomogramtopredictsurvivalofpatientswithadvancedandmetastaticpancreaticcancer